Jeil Pharm (002620) — Cash Flow Reinvestment Rate

Latest as of December 2025: 1.27x

Jeil Pharm (002620) has a Cash Flow Reinvestment Rate of 1.27x as of December 2025, reinvesting ₩2.51 Billion (capex ₩2.26 Billion plus investments ₩-246.34 Million) from operating cash flow of ₩1.97 Billion. Explore 002620 capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.27x
(Capex + Investments) / Operating CF

Total Reinvested

₩2.51 Billion
Capex + Investments

Operating Cash Flow

₩1.97 Billion
KRW

Capital Expenditures

₩2.26 Billion
KRW

Jeil Pharm Cash Flow Reinvestment Rate (2011–2025)

Historical reinvestment intensity for Jeil Pharm across 8 annual periods. Also explore total assets of Jeil Pharm for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Jeil Pharm (2011–2025)

Year-by-year capital reinvestment analysis for Jeil Pharm. For live market cap and broader valuation context, see 002620 company net worth.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2025 41.01x ₩16.00 Billion ₩390.26 Million ₩9.33 Billion ▲ +1111.8%
2024 3.38x ₩15.37 Billion ₩4.54 Billion ₩6.86 Billion ▲ +32.6%
2021 2.55x ₩34.19 Billion ₩13.40 Billion ₩23.69 Billion ▲ +44.8%
2019 1.76x ₩44.43 Billion ₩25.22 Billion ₩37.69 Billion ▲ +107.5%
2017 0.85x ₩5.03 Billion ₩5.92 Billion ₩2.94 Billion ▼ -84.0%
2016 5.30x ₩60.20 Billion ₩11.36 Billion ₩30.33 Billion ▲ +87.4%
2015 2.83x ₩7.76 Billion ₩2.74 Billion ₩6.74 Billion ▲ +159.0%
2011 1.09x ₩25.82 Billion ₩23.63 Billion ₩22.40 Billion
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow